Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06977074) titled 'PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC' on May 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sun Yat-sen University

Condition: Non-small Cell Lung Cancer (NSCLC)

Intervention: Drug: PD-1 inhibitor

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: May 10, 2025

Target Sample Size: 83

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06977074

Published by HT Digital Content...